11 patents
Utility
Compositions and Methods for Treating Allograft Vasculopathy, Moyamoya Disease, Moyamoya Syndrome and Intimal Proliferation
18 Jan 24
The present disclosure provides compositions and methods for treating allograft vasculopathy, for treating Moyamoya Diseases (MMD) and Moyamoya Syndrome (MMS), for treating inhibiting or preventing unwanted intimal proliferation in a subject by administering an ectonucleotide pyrophosphatase phosphodiesterase-1 (ENPP1) agent or an ectonucleotide pyrophosphatase phosphodiesterase-3 (ENPP3).
Damon Banks, Catherine A. Nester, Edward Skolnik, Markus Walz, Frank Rutsch, Yvonne Nitschke
Filed: 30 Dec 22
Utility
Compositions and Methods for Treating Peripheral Artery Disease
23 Nov 23
The present disclosure provides compositions and methods for treating Peripheral Artery Diseases in a subject by administering an ectonucleotide pyrophosphatase phosphodiesterase-1 (ENPP1) agent or an ectonucleotide pyrophosphatase phosphodiesterase-3 (ENPP3).
David Thompson, Frank Rutsch, Yvonne Nitschke
Filed: 23 Nov 22
Utility
Compositions and Methods for Inhibiting Vascular Smooth Muscle Cell Proliferation
19 Oct 23
The present disclosure provides compositions and methods for treating vascular smooth muscle cell proliferation in a subject that does not have a deficiency of ectonucleotide pyrophosphatase phosphodiesterase-1 (ENPP1) resulting in a pathological disease of calcification or ossification by administering an ENPP1 agent or an ENPP3 agent.
Frank Rutsch, David Thompson, Yvonne Nitschke, Robert Terkeltaub
Filed: 23 Nov 22
Utility
Soluble ENPP1 Proteins and Uses Thereof
5 Oct 23
In certain aspects, the present invention provides novel soluble ENPP1 or ENPP3 polypeptides, as well as compositions and methods for using those variants to treat an indication associated an ENPP1 or ENPP3 deficiency.
Zhiliang Cheng, Demetrios Braddock, Paul Stabach, Steven Jungles
Filed: 8 Dec 22
Reissue
Methods of treating tissue calcification
16 May 23
The present invention provides a method of treating NPP1 deficiency or NPP1-associated disease such as idiopathic infantile arterial calcification (IIAC), pseudoxanthoma elasticum, vascular calcification in chronic kidney disease (VCCKD), insulin resistance, hypophosphatemic rickets, myocardial ischemia, joint calcification, angioid streaks, and ossification of the posterior longitudinal ligament of the spine.
Anthony Quinn, Nelson Hsia, Tayeba Khan, Kim Lynette Askew, Gregory Grabowski, Zhiliang Cheng, W. Charles O'Neill
Filed: 3 Dec 20
Utility
NPP1 Fusion Proteins
27 Apr 23
The present invention provides a novel fusion polypeptide containing a catalytic domain of NPP1 fused to a targeting moiety, nucleic acids encoding the fusion polypeptide, a vector containing the nucleic acid integrated thereinto, a host cell transformed with the vector and pharmaceutical compositions comprising the fusion polypeptide.
Anthony Quinn, Alex J. Harvey, Zhinan Xia
Filed: 11 Aug 22
Utility
Treatment of Diseases Involving Deficiency of ENPP1 or ENPP3
2 Feb 23
The present disclosure provides, among other things, vectors for expression of ENPP1 or ENPP3 in vivo and methods for the treatment of diseases of calcification and ossification in a subject.
Steven Jungles, Demetrios Braddock
Filed: 25 Aug 22
Utility
Methods of Treating Myointimal Proliferation
10 Nov 22
The present invention provides a method of treating myointimal proliferation by administering a recombinant human soluble ectonucleotide pyrophosphatase phosphodiesterase (hsNPP1), active fragment or fusion protein thereof.
Yan YAN, Anumeha SHAH, Ashmita SAIGAL, Herman GRIFFIN, Susan Faas MCKNIGHT, Andre MAROZSAN, Kim ASKEW, Yvonne NITSCHKE, Frank RUTSCH
Filed: 18 May 22
Utility
Methods of treating myointimal proliferation
21 Jun 22
The present invention provides a method of treating myointimal proliferation by administering a recombinant human soluble ectonucleotide pyrophosphatase phosphodiesterase (hsNPP1), active fragment or fusion protein thereof.
Yan Yan, Anumeha Shah, Ashmita Saigal, Herman Griffin, Susan Faas McKnight, Andre Marozsan, Kim Askew, Yvonne Nitschke, Frank Rutsch
Filed: 15 Jun 17
Utility
NPP1 Fusion Proteins
30 Sep 21
The present invention provides a novel fusion polypeptide containing a catalytic domain of NPP1 fused to a targeting moiety, nucleic acids encoding the fusion polypeptide, a vector containing the nucleic acid integrated thereinto, a host cell transformed with the vector and Pharmaceutical compositions comprising the fusion polypeptide.
Anthony Quinn, Alex J. Harvey, Zhinan Xia
Filed: 25 Nov 20
Utility
Treatment of Diseases Involving Deficiency of ENPP1 or ENPP3
24 Jun 21
The present disclosure provides, among other things, vectors for expression of ENPP1 or ENPP3 in vivo and methods for the treatment of diseases of calcification and ossification in a subject.
Steven Jungles, Demetrios Braddock
Filed: 17 Feb 21
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first